In a randomised phase 2 trial in relapsed/refractory classic Hodgkin lymphoma (147 randomised, 132 analysed), adding ipilimumab to BV/nivolumab did not significantly raise complete response (70.3% vs 64.7%, P=.29); grade 3 rash was more common (24.6% vs 9.2%).
RCTn = 147
Diefenbach et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma